A Phase 2 clinical trial involving degarelix has been updated with a status change to withdrawn, as of October 1, 2026. The study, registered as NCT01630967, was titled "Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)."
The trial was designed to evaluate switching patients from an LHRH agonist to an LHRH antagonist, degarelix, in the setting of progressive castrate resistant prostate cancer. It was registered under Phase 2 status.
The current record lists the trial status as withdrawn. No results or outcome data are included in this update. The withdrawal designation reflects the current clinical trial record status only and does not by itself indicate findings about degarelix's effects.
Degarelix remains an approved compound. This update pertains only to the status of this specific registered trial and does not describe new safety or efficacy data.
Readers seeking general background on this compound can consult the degarelix overview page for additional context.